Reckamp, K. L., Giaccone, G., Camidge, D. R., Gadgeel, S. M., Khuri, F. R., Engelman, J. A., . . . Jänne, P. A. (2014). A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib. Wiley.

Reckamp, Karen L., et al. A Phase 2 Trial of Dacomitinib (PF‐00299804), an Oral, Irreversible Pan‐HER (human Epidermal Growth Factor Receptor) Inhibitor, in Patients With Advanced Non–small Cell Lung Cancer After Failure of Prior Chemotherapy and Erlotinib. Wiley, 2014.

Reckamp, Karen L., et al. A Phase 2 Trial of Dacomitinib (PF‐00299804), an Oral, Irreversible Pan‐HER (human Epidermal Growth Factor Receptor) Inhibitor, in Patients With Advanced Non–small Cell Lung Cancer After Failure of Prior Chemotherapy and Erlotinib. Wiley, 2014.